Abstract
BackgroundTofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Two Phase 3 studies have been completed (NCT01877668; NCT01882439) and a long-term extension (LTE)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have